Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1 Peptide Vaccine and Toripalimab in Metastatic Ovarian Cancer
NCT05479045Phase 2Withdrawn
- Sponsor
- Georgetown University
- Start
- Sep 2026
- Primary completion
- Nov 2027
- Modality
- Peptides, Vaccines & Immunotherapeutics
01
Overview
A Phase 2 trial of NY-ESO-1b peptide vaccine, toripalimab in ovarian cancer, sponsored by Georgetown University. Planned start Sep 2026; status: withdrawn.
02
Drugs
NY-ESO-1b peptide vaccinetoripalimab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05479045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05479045.